Seaport Therapeutics set terms this week for a $201 million initial public offering, the first neuropsychiatric-focused biotech to attempt a nine-figure U.S. listing since mid-2023. Pricing is scheduled before Friday's close. The company is offering 11.8 million shares at $16 to $18, a range that values the business at roughly $970 million post-money if the midpoint clears.

Seaport is a Boston spinout building a pipeline around CNS disorders — major depressive disorder, post-traumatic stress, Huntington's chorea. Lead asset STP-369, a GABA-A modulator, entered Phase II trials in September 2024. Second program STP-939 targets Huntington's with a kynurenine pathway inhibitor, Phase I data due mid-year. The company has no revenue, burned $63 million in the nine months through September, and carries $18 million cash on the balance sheet. The raise puts eighteen months of runway on the books if burn stays flat.

This matters because life-science IPOs vanished after the Fed's first 75-basis-point hike in June 2022. Biotech indices fell 41 percent peak-to-trough through October 2023, and the primary market stayed shut even as indices recovered 28 percent off the lows in 2024. Seaport is testing whether institutional demand has returned for clinical-stage neuroscience, a category that historically required twice the cash and twice the time of oncology programs. If the deal prices at or above midpoint, it signals that long-duration science plays are back in favor with crossover funds. If it prices below $16 or pulls, the window is still closed for anything without Phase III data.

The timing is deliberate. Seaport filed confidentially in October, amended publicly in December, and timed pricing for a week when the S&P Biotech ETF (XBI) sits 11 percent above its 200-day moving average and the NASDAQ Biotech Index just posted its best January in three years. Underwriters are J.P. Morgan, Jefferies, and Leerink — the same trio that priced Vor Biopharma at $16 in February 2021, a deal that now trades at $2.80. Seaport's backers include OrbiMed, Nextech, and Deerfield, three shops that have been trapped in late-stage privates for twenty-four months. They are taking liquidity at a 1.4x step-up from the last preferred round in Q2 2023, a modest return that reflects desperation more than conviction.

Watch whether the deal closes inside the range, and whether trading volume on day two holds above 3 million shares. If it does, expect two or three more neuroscience IPOs to file before March, likely from the same venture syndicates. If Seaport breaks issue within ten days, the window closes again and late-stage CNS companies go back to inside rounds at flat or down valuations. Also watch STP-369 Phase II interim data, due April. A clean readout moves the stock; a messy one confirms that the market priced in binary risk at 60 cents on the dollar.

The real tell is how much of the book comes from crossover funds versus biotech specialists. If Fidelity, T. Rowe, or Wellington show up in the next 13F, the life-science IPO market is back. If the register is all Perceptive, RTW, and RA Capital, this was a syndicate rescue dressed as a public offering.